Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Cash & Equivalents (2020 - 2022)

Atea Pharmaceuticals has reported Cash & Equivalents over the past 3 years, most recently at $176.4 million for Q3 2022.

  • Quarterly results put Cash & Equivalents at $176.4 million for Q3 2022, down 78.99% from a year ago — trailing twelve months through Sep 2022 was $176.4 million (down 78.99% YoY), and the annual figure for FY2021 was $764.4 million, down 10.09%.
  • Cash & Equivalents for Q3 2022 was $176.4 million at Atea Pharmaceuticals, down from $684.5 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for AVIR hit a ceiling of $850.1 million in Q4 2020 and a floor of $17.1 million in Q1 2020.
  • Median Cash & Equivalents over the past 3 years was $705.5 million (2022), compared with a mean of $537.2 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 4762.37% in 2021 and later plummeted 78.99% in 2022.
  • Atea Pharmaceuticals' Cash & Equivalents stood at $850.1 million in 2020, then decreased by 10.09% to $764.4 million in 2021, then crashed by 76.92% to $176.4 million in 2022.
  • The last three reported values for Cash & Equivalents were $176.4 million (Q3 2022), $684.5 million (Q2 2022), and $705.5 million (Q1 2022) per Business Quant data.